Recombinant Human CD19 Protein, Fc-Avi-tagged, Biotinylated

• Cat.No.: CD19-281H
• Product Overview: Biotinylated Human CD19 (20-291), Fc,Avitag is expressed from human 293 cells (HEK293). It contains AA Pro 20 - Lys 291 (Accession # P15391-1).

Specification

• Description: B-lymphocyte antigen CD19 is also known as CD19 (Cluster of Differentiation 19), is a single-pass type I membrane protein which contains two Ig-like C2-type (immunoglobulin-like) domains. CD19 is expressed on follicular dendritic cells and B cells. In fact, it is present on B cells from earliest recognizable B-lineage cells during development to B-cell blasts but is lost on maturation to plasma cells. It primarily acts as a B cell co-receptor in conjunction with CD21 and CD81. Upon activation, the cytoplasmic tail of CD19 becomes phosphorylated, which leads to binding by Src-family kinases and recruitment of PI-3 kinase. As on T cells, several surface molecules form the antigen receptor and form a complex on B lymphocytes. The (almost) B cell-specific CD19 phosphoglycoprotein is one of these molecules. The others are CD21 and CD81. These surface immunoglobulin (sIg)-associated molecules facilitate signal transduction. On living B cells, anti-immunoglobulin antibody mimicking exogenous antigen causes CD19 to bind to sIg and internalize with it. The reverse process has not been demonstrated, suggesting that formation of this receptor complex is antigen-induced. This molecular association has been confirmed by chemical studies. Mutations in CD19 are associated with severe immunodeficiency syndromes characterized by diminished antibody production. CD19 has been shown to interact with: CD81, CD82, Complement receptor 2, and VAV2.
• Source: HEK293
• Species: Human
• Tag: Fc-Avi
• Predicted N Terminal: Pro 20
• Form: Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.
• Molecular Mass: The protein has a calculated MW of 58.9 kDa. The protein migrates as 65-80 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
• Protein length: Pro 20 - Lys 291
• Endotoxin: Less than 1.0 EU per μg by the LAL method.
• Purity: >90% as determined by SDS-PAGE.
• Storage: For long term storage, the product should be stored at lyophilized state at -20°C or lower.
  Please avoid repeated freeze-thaw cycles.
  This product is stable after storage at:
  -20°C to -70°C for 12 months in lyophilized state;
  -70°C for 3 months under sterile conditions after reconstitution.
• Reconstitution: It is recommended that sterile water be added to the vial to prepare a stock solution of 0.2 ug/ul. Centrifuge the vial at 4℃ before opening to recover the entire contents.

Gene Information

• Gene Name: CD19 CD19 molecule [ Homo sapiens ]
• Official Symbol: CD19
• Synonyms: CD19; B4; CVID3; MGC12802
• Gene ID: 930
• mRNA Refseq: NM_001178098
• Protein Refseq: NP_001171569
• MIM: 107265
• UniProt ID: P15391

Reviews

01/02/2023

The manufacturer of CD19 protein has consistently provided outstanding technical support that has surpassed my expectations.

08/18/2022

This protein demonstrates remarkable purity, stability, and specificity, ensuring utmost accuracy and reproducibility in my research endeavors.

06/29/2016

Their dedication to customer satisfaction has been instrumental in overcoming obstacles and achieving successful results in my experiments.

Q&As

How does CAR-T cell therapy work to combat CD19-expressing cancers?

CAR-T cells are engineered to express a receptor that recognizes CD19 on the surface of cancerous B cells. When they encounter these cells, they destroy them.

Are there any diseases associated with CD19 dysfunction?

CD19 deficiencies can lead to primary immunodeficiencies, making individuals more susceptible to infections.

What are the potential side effects of CAR-T cell therapy targeting CD19?

Side effects may include cytokine release syndrome (CRS), neurologic toxicity, and long-term B-cell aplasia.

What are some CD19-expressing malignancies that CAR-T cell therapy can target?

CAR-T cell therapy is used to treat B-cell malignancies such as acute lymphoblastic leukemia (ALL) and certain types of non-Hodgkin lymphoma.

How effective is CAR-T cell therapy in treating CD19-expressing cancers?

CAR-T cell therapy has shown remarkable effectiveness in inducing remissions in patients with CD19-positive malignancies, particularly in those who have relapsed or failed conventional treatments.